Related Experiment Video
Updated: Mar 7, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.3K
Large primary pleural synovial sarcoma with severe dyspnea: a case report
Minoru Yamaki1, Shuji Yonehara2, Toshio Noriyuki3,4
1Department of Surgery, Onomichi General Hospital, 1-10-23 Hirahara, Onomichi, Hiroshima, 722-8508, Japan.
Surgical Case Reports
|February 17, 2017
Summary
This case study details a rare pleural synovial sarcoma in a 62-year-old man, successfully treated with surgery, radiation, and chemotherapy. The patient remains recurrence-free one year post-treatment, highlighting effective management for this uncommon soft tissue sarcoma.
Area of Science:
- Oncology
- Thoracic Surgery
- Pathology
Background:
- Synovial sarcoma, a rare soft tissue malignancy, primarily affects extremities.
- Primary pleural and lung synovial sarcoma is exceptionally uncommon.
- This report focuses on a unique case of large pleural synovial sarcoma.
Purpose of the Study:
- To present a rare case of primary pleural synovial sarcoma.
- To discuss the diagnostic challenges and treatment approach for this rare condition.
- To highlight the successful management of a large pleural synovial sarcoma presenting with severe dyspnea.
Main Methods:
- A 62-year-old male patient presented with fatigue and severe dyspnea.
- Initial diagnosis via CT-guided needle biopsy suggested sarcomatoid mesothelioma.
- Treatment involved pleuropneumonectomy, followed by radiotherapy and adjuvant chemotherapy (ifosfamide and Adriamycin).
Main Results:
- A 22-cm pleural tumor was resected, diagnosed as monophasic synovial sarcoma.
- The patient experienced severe dyspnea attributed to pulmonary collapse.
- One year post-treatment, the patient shows no signs of tumor recurrence.
Conclusions:
- Large pleural synovial sarcoma can present with significant respiratory compromise.
- Multimodal treatment including surgical resection, radiotherapy, and chemotherapy can be effective.
- Complete tumor resection and adjuvant therapy are crucial for disease control in such rare cases.
